Proteasome inhibitors in multiple myeloma: 10 Years later

Blood

Volumn 120, Issue 5, 2012, Pages 947-959

  Moreau, Philippe ^a   Richardson, Paul G ^b   Cavo, Michele ^c   Orlowski, Robert Z ^d   San Miguel, Jesuś F ^e   Palumbo, Antonio ^f   Harousseau, Jean Luc ^g  

^a HÔTEL DIEU   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CSIC   (Spain)

^f MOLINETTE HOSPITAL   (Italy)

^g Institut Cancérologique de l'Ouest   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; PANOBINOSTAT; PERIFOSINE; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE B INHIBITOR; SALINOSPORAMIDE A; THALIDOMIDE; VINCRISTINE; VORINOSTAT;

ADD ON THERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COGNITIVE DEFECT; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LIMB PAIN; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NEPHROTOXICITY; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RELAPSE; RETREATMENT; REVIEW; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VOMITING;

EID: 84864568543     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-403733     Document Type: Review

References (100)

1. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(Suppl 1):3-9. (Pubitemid 36626287)
2. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79(1):13-21. (Pubitemid 24309509)
3. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998;17(24):7151-7160. (Pubitemid 29002684)
4. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997;386(6624):463-471. (Pubitemid 27164066)
5. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-4916. (Pubitemid 43882644)
6. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat. 1999;2(4):215-223. (Pubitemid 29526245)
7. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349-360. (Pubitemid 38579481)
8. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anticancer therapy. Drug Discov Today. 2010;15(5):243-249.
9. Jain S, Diefenbach C, Zain J, O'Connor OA. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid. 2011;6:43-57.
10. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970- 1980.
11. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005;5(1):18.
12. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol. 2010;21(9):1756-1764.
13. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-2042.
14. .Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16(16):4094-4104.
15. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence [published online ahead of print January 6, 2012]. Cancer Treat Rev. doi:10.1016/j.ctrv.2011.12.007.
16. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765-2775.
17. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383-6391. (Pubitemid 47037522)
18. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734-2743.
19. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290. (Pubitemid 350106321)
20. Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116(23):4906-4915.
21. Hurchla MA, Garcia-Gomez A, Hornick MC, et al. Epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable ONX 0912 have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1253. Abstract 2906.
22. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8(5):407-419. (Pubitemid 41579835)
23. Potts C, Albitar X, Anderson C, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011;11(3):254-284.
24. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8(8):2505-2511. (Pubitemid 34856332)
25. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420-4427. (Pubitemid 35334752)
26. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22(11):2108-2121. (Pubitemid 41095144)
27. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
28. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-172. (Pubitemid 39371809)
29. Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537-540.
30. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487- 2498. (Pubitemid 41007864)
31. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-3560. (Pubitemid 350159621)
32. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204(1):317-325. (Pubitemid 46330280)
33. Csizmadia V, Raczynski A, Csizmadia E, et al. Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. Neurotoxicology. 2008;29(2):232-243.
34. Silverman L, Csizmadia V, Brewer K, Simpson C, Alden C. Proteasome inhibitor associated neuropathy is mechanism based [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):2646a. Abstract 2646.
35. Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086-1095.
36. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-319.
37. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595-608.
38. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program. 2010:423-430.
39. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
40. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
41. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-5109.
42. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
43. San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11(1):51-61. (Pubitemid 43152686)
44. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777-3784. (Pubitemid 41739012)
45. Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93(12):1908-1911.
46. Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma: results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 2010;79(3-4):247-254.
47. Petrucci MT, Blau I, Corradini P, et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study [abstract]. Haematologica. 2010;95(s2):152. Abstract 0377.
48. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377-2380. (Pubitemid 36302084)
49. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058-3065.
50. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. (Pubitemid 47477266)
51. Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13-23.
52. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929-934. (Pubitemid 44023146)
53. Mikhael JR, Belch AR, Prince HM, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009;144(2):169-175.
54. Garderet L, Iacobelli S, Moreau P, et al. Bortezomib (VELCADE)- thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation [abstract]. Haematologica. 2011;96(s2):420-421. Abstract 1008.
55. Dimopoulos MA, Jagannath S, Yoon S-S, et al. Vantage 088. Vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):368-369. Abstract 811.
56. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17(6):1264-1277.
57. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108(7):2165-2172.
58. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93(4):560-565. (Pubitemid 351536384)
59. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
60. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
61. San Miguel JF, Schlag R, Khuageva NK, et al. Continued overall survival benefit after 5 years'follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):221-222. Abstract 476.
62. Mateos MV, Oriol A, Teruel AI, et al. Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):222. Abstract 477.
63. Corso A, Barbarano L, Mangiacavalli S, et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leuk Lymphoma. 2010;51(2):236-242.
64. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498-1505. (Pubitemid 44736116)
65. Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009;146(6):619-626.
66. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629.
67. .Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12(3):235-239. (Pubitemid 46930250)
68. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009;27(30):5015-5022.
69. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141(4):512-516. (Pubitemid 351550543)
70. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
71. Reeder CB, Reece DE, Kukreti V, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-3417.
72. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.
73. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118(22):5752-5758.
74. Rosiñol L, Cibeira MT, Mateos MV, et al. Results of pre- and post-autologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): superiority of VTD (bortezomib/thalidomide/ dexamethasone) over TD and VBMCP/VBAD plus bortezomib (VBMCP/VBAD/V) [abstract]. Haematologica. 2011;96(s1):S69. Abstract P-138.
75. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):23-24. Abstract 40.
76. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063- 6073.
77. Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010;115(1):32-37.
78. Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16(20):5079-5086.
79. Mellqvist UH, Gimsing P, Hjertner O, et al. Improved progression-free survival with bortezomib consolidation after high dose melphalan: results of a randomized phase III trial [abstract]. Haematologica. 2011;96(s1):S31. Abstract O-11.
80. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-2084.
81. Ladetto M, Ferrero S, Drandi D, et al. Long-term results of the GIMEMA VTD consolidation trial in autografted multiple myeloma patients (VEL-03-096): impact of minimal residual disease detection by real time quantitative PCR on late recurrences and overall survival [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):376-377. Abstract 827.
82. Cavo M, Pantani L, Patriarca F, et al. Superior complete response rate (CR) and progressionfree survival (PFS) with bortezomib-thalidomide- dexamethasone (VTD) versus thalidomidedexamethasone (TD) as consolidation therapy after autologous stem-cell transplantation (ASCT) in multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):816. Abstract 1871.
83. Sahebi F, Frankel PH, Farol L, et al. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2012;18(3):486-492.
84. Rosiñol L, Cibeira MT, Mateos MV, et al. A phase III PETHEMA/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: superiority of bortezomib/thalidomide compared with thalidomide and alfa-2b interferon [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1694-1695. Abstract 3962.
85. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma [published online ahead of print May 3, 2012]. Blood. doi:10.1182/blood-2012-03-414359.
86. Vij R, Siegel DS, Kaufman JL, et al. Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM) [abstract]. J Clin Oncol. 2010;28(15s):573s. Abstract 8000.
87. Singhal S, Siegel DS, Martin T, et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):819. Abstract 1876.
88. Siegel DS, Martin T, Wang M, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):433. Abstract 985.
89. Jakubowiak AJ, Martin T, Singhal S, et al. Responses to single-agent carfilzomib (CFZ) are not affected by cytogenetics in patients (pts) with relapsed and refractory multiple myeloma (R/R MM) [abstract]. Ann Oncol. 2011;22(Suppl 4):iv122. Abstract 117.
90. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):128-129. Abstract 304.
91. Sonneveld P, Hacker E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM): a trial of the European Myeloma Network EMN [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):290. Abstract 633.
92. Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(12):288-289. Abstract 631.
93. Richardson PG, Spencer A, Cannell P, et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):140-141. Abstract 302.
94. Assouline S, Chang J, Rifkin R, et al. MLN9708, a novel, investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma: results of a phase 1 dose-escalation study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1148. Abstract 2672.
95. Berdeja JG, Richardson PG, Lonial S, et al. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):223. Abstract 479.
96. Kumar S, Bensinger WI, Reeder CB, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):371-372. Abstract 816.
97. Richardson PG, Baz R, Wang L, et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):140. Abstract 301.
98. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316-1319. (Pubitemid 43363908)
99. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):222-223. Abstract 478.
100. Jagannath S, Vij R, Stewart AK, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol. 2009;27(15s):435s. Abstract 8504.